Access to Innovation: Dissecting Big Pharma and Biotech's Renewed Interest in Early Stage DealsGautam Aggarwal, a Senior Practice Executive in our Business Development Practice, will present a session titled, "Access to Innovation: Dissecting Big Pharma and Biotech's Renewed Interest in Early Stage Deals"
Access to Innovation: Dissecting Big Pharma and Biotech's Renewed Interest in Early Stage Deals
Pharma companies are increasingly reliant on external research to fill their pipelines. This session will look at the strategic approach of pharma and large biotech companies to access innovation in the future including an increase in early stage deal activity. The market for post-proof-of-concept assets drew significant competition over the past two years, with most assets getting a good hard look from potential partners. As unpartnered late stage assets begin to appear picked-over, larger companies have more recently turned their heads toward early stage deals, where deal terms have gone from modest to eye-popping, especially in popular therapeutic areas. In addition, larger companies have started to express interest in investing in specific mechanisms of action rather than just disease states as a whole, leading to a secondary level of competition in some classes.
Compounding this new licensing environment is the trade-off that many large companies are making to invest in arguably higher risk early stage assets rather than the potential for quick return of commercial-ready assets that could seamlessly fill “the bag” of their existing sales force. Between in-licensing, acquisitions, collaborative approaches and corporate venture programs, which models will allow the greatest access to innovation in the future?
Moderator: Gautam Aggarwal – Senior Practice Executive, Campbell Alliance